论文部分内容阅读
目的:研究西格列汀对2型糖尿病患者微量白蛋白尿的影响,分析其可能机制和临床应用价值。方法:选取160例伴微量白蛋白尿的2型糖尿病患者,随机分为西格列汀组和其他药物组,各80例。比较两组患者治疗前和治疗3个月后血糖水平、尿微量白蛋白、超敏C反应蛋白及血浆还原型谷胱甘肽水平。结果:经3个月治疗,两组患者空腹血糖、餐后2 h血糖、Hb A1c均较治疗前下降,但差异无明显统计学意义(P>0.05);西格列汀治疗组患者尿微量白蛋白和血浆Hs-CRP水平明显下降,血浆还原型谷胱甘肽水平明显升高,与其他口服药物治疗组相比差异具有统计学意义(P<0.05)。结论:西格列汀可能通过改善机体炎症状态,降低氧化和应激水平等机制降低2型糖尿病患者的尿微量白蛋白水平。
Objective: To study the effect of sitagliptin on microalbuminuria in patients with type 2 diabetes mellitus, and to analyze its possible mechanism and clinical value. Methods: A total of 160 patients with type 2 diabetes mellitus with microalbuminuria were randomly divided into sitagliptin group and other drug groups, 80 cases each. Blood glucose, urine microalbumin, high-sensitivity C-reactive protein and plasma reduced glutathione levels were compared between the two groups before treatment and after 3 months of treatment. Results: After 3 months of treatment, fasting blood glucose, postprandial blood glucose 2 h, Hb A1c in both groups decreased compared with before treatment, but the difference was not statistically significant (P> 0.05) Albumin and plasma levels of Hs-CRP decreased significantly, plasma reduced glutathione levels were significantly increased, compared with other oral drug treatment group, the difference was statistically significant (P <0.05). Conclusion: Sogliptin may reduce urinary albumin levels in type 2 diabetic patients by improving the inflammatory state of the body and reducing the levels of oxidative stress and stress.